<DOC>
	<DOCNO>NCT00332566</DOCNO>
	<brief_summary>This booster study assess immunogenicity , reactogenicity safety booster dose GSK Biologicals ' DTPw-HBV/Hib Kft . vaccine versus DTPw-HBV/Hib vaccine , healthy child , 18 24 month age , receive vaccine primary vaccination . Prior booster dose , study also assess persistence antibody vaccine antigen component administer primary vaccination course . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Assess Immunogenicity , Reactogenicity , Safety Booster GSK Biologicals DTPw-HBV/Hib Kft Compared DTPw-HBV/Hib</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrol study . A male female toddler , 18 24 month age time booster vaccination , complete threedose primary vaccination course 101223 study . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede booster dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior booster vaccine dose . Planned administration/ administration vaccine foreseen study protocol period start 30 day end 30 day administration booster vaccine dose , exception oral polio vaccine ( OPV ) . Previous booster vaccination diphtheria , tetanus , pertussis , hepatitis B Hib disease since conclusion visit 101223 study . History diphtheria , tetanus , pertussis , hepatitis B Hib disease . Known exposure diphtheria , tetanus , pertussis , hepatitis B Hib disease since conclusion visit 101223 study . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination History allergic disease reaction likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrolment . Administration immunoglobulins and/or blood product study period . Other condition opinion investigator may potentially interfere interpretation study outcomes . One follow adverse event constitute absolute contraindication administration DTP vaccine , occur previous administration DTPw vaccine . Known hypersensitivity component vaccine , show sign hypersensitivity previous administration diphtheria , tetanus , pertussis HB vaccine . Encephalopathy Axillary temperature &gt; = 40 °C/ rectal temperature &gt; = 40.5 °C within 48 hour vaccination . Collapse shocklike state within 48 hour vaccination . Persistent , inconsolable cry last &gt; = 3 hour occur within 48 hour vaccination . Seizures without fever occur within 3 day vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>